Galleri Blood Test Fails to Meet Primary Goal in Landmark Cancer Screening Trial
Results from the largest randomized controlled trial of a multi-cancer early detection (MCED) blood test, Galleri, have raised significant questions about its effectiveness in reducing late-stage cancer diagnoses. The study, involving 142,942 participants in the UK, found that the test did not meet its primary endpoint of lowering the incidence of advanced-stage cancers, despite generating some promising secondary findings.
Study Design and Objectives
The Galleri-NHS trial, presented at the American Society of Clinical Oncology (ASCO) annual meeting, aimed to evaluate whether integrating the Galleri test with standard cancer screening could detect cancers at earlier, more treatable stages. Participants aged 50 to 77, who had no cancer symptoms, were randomly assigned to either receive annual Galleri testing or standard screening alone. Those with positive Galleri results underwent additional diagnostic evaluations, as did all participants who developed cancer-related symptoms.
The primary endpoint focused on reducing stage three and stage four diagnoses for 12 specific cancers. However, the trial found no statistically significant difference in advanced-stage cancer rates between the two groups.
Mixed Results and Expert Reactions
While the trial did not meet its main goal, researchers noted a 14% reduction in stage four cancer diagnoses among Galleri participants—a finding Grail, the test’s developer, highlighted as evidence of potential early detection benefits. “Galleri represents a potential transformational shift in cancer detection,” said Harpal Kumar, Grail’s chief scientific officer, who previously led Cancer Research UK.
However, independent experts remain cautious. Professor Richard Houlston of the Institute of Cancer Research emphasized that the study’s primary endpoint was not met, and the observed reductions in late-stage cancers require further validation. “There is no evidence base to justify population-scale implementation of Galleri at this time,” he stated.
Implications for Cancer Screening
The NHS, which funded the trial, has yet to announce a formal response. Professor Peter Johnson, NHS England’s national clinical director for cancer, noted that detailed data analysis is ongoing. “We look forward to reviewing the findings to inform future decisions,” he said.
The results underscore the challenges of translating early-stage cancer detection technologies into clinical practice. While Galleri and similar tests offer hope for non-invasive screening, their real-world impact remains to be determined through long-term studies tracking mortality outcomes.
What’s Next?
Researchers plan to continue monitoring participants for several years to assess whether early detection translates to improved survival rates. Meanwhile, the trial highlights the need for rigorous, large-scale studies to validate emerging diagnostic tools before widespread adoption.
As the field of liquid biopsy advances, stakeholders agree that transparency and scientific rigor will be critical to ensuring these innovations deliver on their promise.